Targets › VEGFC
2 programs from 2 companies in 6 trials: 3 Phase 3, 1 Phase 2, 1 Phase 1, 1 Phase 4; Ophthalmology; next expected readout Mar 2027.
Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. (UniProt, P49767)
Open in Phaseline: the race on VEGFC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai Eye Disease Prevention and Treatment Center | Conbercept Vascular endothelial growth factor A inhibitor; Vascular endothelial growth factor B inhibitor; Placenta growth factor inhibitor | VEGFA, VEGFB, PGF, VEGFC | Phase 4 | Diabetic Macular Edema | – |
| 4D Molecular Therapeutics | 4D-150 AAV-based gene therapy delivering miRNA targeting VEGF-C and codon-optimized aflibercept s | VEGFA, VEGFC, VEGFR2 | Phase 3 | Macular Neovascularization Secondary to Age-Related Macular Degeneration; Neovascular Age-Related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Diabetic Macular Edema … | Mar 2027 |
Diabetic Macular Edema (2) Macular Neovascularization Secondary to Age-Related Macular Degeneration (1) Neovascular Age-Related Macular Degeneration (nAMD) (1) Diabetic Macular Edema (DME) (1) Neovascular (Wet) Age-Related Macular Degeneration (1)
mixed (1), antibody (1)
4D Molecular Therapeutics (1) Shanghai Eye Disease Prevention and Treatment Center (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.